One Time. For a Lifetime.
Protection against stroke risk. Protection against oral anticoagulant (OAC) bleed risk. The WATCHMAN Implant is the one-time, minimally invasive procedure that protects your atrial fibrillation (AFib) patients for life.
Over 600,000 AFib patients have left blood thinners behind, replacing OACs with the WATCHMAN Left Atrial Appendage Closure (LAAC) Implant.1
Proven1
10 years
FDA approved
20+ years
clinical experience
Safe2
99%
implant success rate*
0.5%
major adverse event rate†
Effective2
96.2%
of patients discontinued OACs at 45 days
Protect your patients: stroke risk reduction without the risks of OACs
Learn more about the WATCHMAN Implant and hear from cardiologists on this safe, OAC alternative for stroke risk reduction.
A proven path toward stroke risk reduction
Stroke risk reduction strategies for patients with AFib continue to evolve, offering more opportunities to individualize care. Left atrial appendage closure (LAAC) is an FDA-approved, clinically validated, non-pharmacologic option for patients who are unable to tolerate long-term OACs.
A growing body of clinical trial data supports earlier consideration of LAAC within the AFib treatment journey. Key trials, including OPTION, PROTECT-AF, PREVAIL, and PRAGUE-17, have shown that WATCHMAN is non-inferior to DOACs and/or warfarin in reducing stroke risk, while demonstrating stroke reduction, implant success, and reduction in major bleeding.3-6 This data, alongside ACC/AHA guidelines, reinforces the WATCHMAN Implant as a proven, safe and effective option for suitable AFib candidates.
Learn more about WATCHMAN
Access resources
Access WATCHMAN resources in the referring HCP download center
Stay connected
Receive monthly updates about the WATCHMAN Implant
Rep visit
Connect with a local representative to learn more about the WATCHMAN Implant
Learn how the WATCHMAN Implant works
*Procedure success defined as successful delivery and release of a WATCHMAN FLX Device into the LAA.
†Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention.
References:
1. Represents all WATCHMAN models.
2. Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021.
3. Wazni O, et al. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. 2025;392:1277-1287.
4. Reddy VY, Holmes D, Doshi SK, et al. Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: The PROTECT AF Trial. Lancet. 2009;374:534–542.
5. Holmes DR, Kar S, Price MJ, et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial. J Am Coll Cardiol. 2014;64:1–12.
6. Osmancik P, Herman D, Neuzil P, et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation: The PRAGUE-17 Trial. Circulation. 2020;142:1612–1622.